Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Alkermes Plc
(NQ:
ALKS
)
22.19
USD
+0.72 (+3.35%)
Official Closing Price
Updated: 5:30 PM EST, Jan 22, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Alkermes Plc
< Previous
1
2
3
4
5
6
7
8
9
...
22
23
Next >
Alkermes Announces Upcoming Presentation at the Bank of America Securities Virtual Health Care Conference
May 06, 2020
Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the 2020 Bank of America Securities Virtual Health Care Conference on Wednesday, May 13, 2020 at 9:40...
From
PR Newswire
Alkermes Launches COVID-19 Relief Fund to Support Innovative Programs Helping Vulnerable Patient Communities
May 04, 2020
- Special Edition of Alkermes Inspiration Grants® Program Designed to Support COVID-19-Related Needs of People Affected by Addiction, Serious Mental Illness or Cancer -
From
PR Newswire
Alkermes Launches COVID-19 Relief Fund to Support Innovative Programs Helping Vulnerable Patient Communities
May 04, 2020
Tags
COVID/19
Health & Healthcare
Philanthropy & Cause Initiatives
From
3BL Media: Corporate Social Responsibility, Energy and Health News
Statement from Alkermes on Response to COVID-19
May 01, 2020
Tags
Healthcare Industry News
Disease Awareness
Mental Health
From
3BL Media: Corporate Social Responsibility, Energy and Health News
Alkermes Plc Reports First Quarter 2020 Financial Results and Provides COVID-19 Related Business Update
April 29, 2020
-- First Quarter Revenues of $246.2 Million, Primarily Driven by 30% Year-Over-Year Growth of Proprietary Product Net Sales --
From
PR Newswire
Alkermes to Host Conference Call to Discuss First Quarter 2020 Financial Results
April 22, 2020
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, April 29, 2020 to discuss the company's first quarter 2020 financial...
From
PR Newswire
Alkermes Announces Publication of Preclinical Data for ALKS 4230 in the Journal for ImmunoTherapy of Cancer
April 22, 2020
- In Preclinical Model, ALKS 4230 Exhibited Improved Anti-tumor Efficacy and Lower Toxicity Relative to Recombinant Human IL-2 -
From
PR Newswire
Journal of Clinical Psychiatry Publishes Data from Alkermes' Phase 3 ENLIGHTEN-1 Efficacy Study of ALKS 3831 in Patients With Schizophrenia
March 04, 2020
Alkermes plc (Nasdaq: ALKS) today announced the publication of results from the phase 3 ENLIGHTEN-1 clinical trial of ALKS 3831 (olanzapine/samidorphan) in the peer-reviewed publication, Journal of...
From
PR Newswire
Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 40th Annual Health Care Conference
February 24, 2020
Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will present at the Cowen and Company 40th Annual Health Care Conference on Monday, March 2, 2020 at 3:30...
From
PR Newswire
Alkermes to Present at the 9th Annual SVB Leerink Global Healthcare Conference
February 19, 2020
Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the SVB Leerink Global Healthcare Conference on Wednesday, Feb. 26, 2020 at 9:00 a.m. ET (2:00 p.m....
From
PR Newswire
Alkermes Plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2019 and Provides Financial Expectations for 2020
February 13, 2020
-- Revenues of $1.17 Billion in 2019, Driven by Year-Over-Year Growth of Proprietary Product Net Sales and VUMERITY® Milestone Payment --
From
PR Newswire
Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2019 Financial Results
February 06, 2020
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Thursday, Feb. 13, 2020, to discuss the company's fourth quarter and year-end 2019...
From
PR Newswire
Alkermes Announces U.S. Food and Drug Administration Acceptance of ALKS 3831 New Drug Application for Treatment of Schizophrenia and Bipolar I Disorder
January 28, 2020
Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's New Drug Application (NDA) seeking approval of ALKS 3831...
From
PR Newswire
Alkermes' Corporate Presentation to be Webcast at the 38th Annual J.P. Morgan Healthcare Conference
January 08, 2020
Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 15, 2020 at 9:00 a.m. PT (12:00...
From
PR Newswire
Alkermes to Present at the Evercore ISI 2nd Annual HealthCONx Conference
November 26, 2019
Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will participate in a fireside chat at the Evercore ISI 2nd Annual HealthCONx Conference on Tuesday, Dec. 3,...
From
PR Newswire
Alkermes Completes Acquisition of Rodin Therapeutics
November 25, 2019
-- Acquisition Expands Alkermes' Research and Development Efforts to Include Small Molecule Therapeutics for Synaptopathies --
From
PR Newswire
Alkermes Submits New Drug Application to U.S. Food and Drug Administration for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder
November 19, 2019
Alkermes plc (Nasdaq: ALKS) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of ALKS 3831 (olanzapine/samidorphan) for...
From
PR Newswire
Alkermes to Acquire Rodin Therapeutics
November 18, 2019
-- Acquisition to Expand Alkermes' Presence in CNS to a Wide Range of Neurodegenerative Diseases Through Epigenetic Control of Synaptogenesis --
From
PR Newswire
Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences
November 12, 2019
Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Stifel 2019 Healthcare Conference on Tuesday, Nov. 19, 2019 at 1:15 p.m. ET (6:15 p.m. GMT) from...
From
PR Newswire
Alkermes Announces Receipt of $150 Million Milestone Payment from Biogen Related to FDA Approval of VUMERITY™
November 12, 2019
Alkermes plc (Nasdaq: ALKS) today announced the receipt of a $150 million milestone payment from Biogen triggered by the recent U.S. Food and Drug Administration (FDA) approval of VUMERITY™ (diroximel...
From
PR Newswire
Alkermes Announces New Data From ALKS 4230 Clinical Development Program at Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
November 08, 2019
̶ Preliminary Safety and Efficacy Data From ARTISTRY-1 Show Signs of Clinical Benefit and Tolerability of ALKS 4230 as Monotherapy and in Combination With Pembrolizumab ̶
From
PR Newswire
Alkermes to Present Data From ALKS 4230 Clinical Development Program at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
November 04, 2019
- Supplemental Materials Will be Made Available on Alkermes' Website on Friday, Nov. 8 -
From
PR Newswire
Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis
October 30, 2019
– VUMERITY, a New Oral Treatment Option for Relapsing Forms of MS, Offers a Combination of Well-Characterized Efficacy, Safety and Tolerability –
From
GlobeNewswire News Releases
Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis
October 30, 2019
- VUMERITY, a New Oral Treatment Option for Relapsing Forms of MS, Offers a Combination of Well-Characterized Efficacy, Safety and Tolerability -
From
PR Newswire
Alkermes Plc Reports Third Quarter 2019 Financial Results and Implementation of Restructuring
October 23, 2019
-- Third Quarter Revenues of $255.2 Million, Primarily Driven by Approximately 20% Year-Over-Year Growth of Proprietary Product Net Sales --
From
PR Newswire
Alkermes Announces Clinical Collaboration With Fred Hutchinson Cancer Research Center for Novel Immuno-Oncology Drug Candidate ALKS 4230
October 21, 2019
-- Planned Phase 2 Multi-Site Trial to Evaluate ALKS 4230 in Combination With Pembrolizumab in Patients With Advanced or Recurrent Head and Neck Squamous Cell Cancer --
From
PR Newswire
Alkermes to Host Conference Call to Discuss Third Quarter 2019 Financial Results
October 16, 2019
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, October 23, 2019, to discuss the company's third quarter 2019 financial...
From
PR Newswire
Alkermes Presents New Health Economics and Outcomes Research on Patients With Schizophrenia and Bipolar I Disorder at 2019 Psych Congress
October 07, 2019
-- Findings From Patient Surveys Underscore Need for New Antipsychotic Treatments With Reduced Side Effects --
From
PR Newswire
Alkermes to Present at the Cantor Fitzgerald Global Healthcare Conference
September 26, 2019
Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference on Thursday, Oct. 3, 2019 at 7:45 a.m. ET (12:45...
From
PR Newswire
Alkermes Announces the Appointment of Richard Gaynor, M.D. and Andy Wilson to its Board of Directors and the Retirement of Director Floyd Bloom, M.D.
September 13, 2019
Alkermes plc (Nasdaq: ALKS) today announced the appointment of two new independent directors, Richard Gaynor, M.D. and Frank Anders (Andy) Wilson, to the company's Board of Directors. The company also...
From
PR Newswire
< Previous
1
2
3
4
5
6
7
8
9
...
22
23
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.